Vinge has advised Neobo Fastigheter AB (publ) (”Neobo”) in connection with the listing of Neobo’s shares on Nasdaq First North Premier. The company description was published on 6 February 2023 and the first day of trading on Nasdaq First North Premier was on 10 February 2023.
Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a directed share issue whereby the company raised proceeds of SEK 210 million before issue costs.
Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) (”SBB”) in connection with the distribution of the shares in Neobo Fastigheter AB (publ) (”Neobo”) to the A and B shareholders in SBB. The resolution on the distribution was adopted at the Extraordinary General Meeting of SBB on 21 December 2022 and the distribution was carried out on 30 December 2022.
Vinge has advised Acrinova AB (publ) (“Acrinova” or the “Company”) in connection with the Company’s uplisting to Nasdaq Stockholm. The prospectus was published on 9 December 2022 and trading on Nasdaq Stockholm commenced on 16 December 2022.
Vinge has advised Hansa Biopharma in connection with a directed share issue through which the company raises proceeds of SEK 415.9 million before transaction costs.
Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore Pharma receives gross proceeds of SEK 200 million.
Vinge has advised BICO Group AB in connection with a directed share issue to Sartorius AG, adding a total amount of MSEK 487 to BICO. The subscription price of SEK 76 was equivalent to a premium of 2.7 per cent compared with a 3-day VWAP. In connection with the share issue, BICO and Sartorius have entered into an extensive co-operation agreement concerning technical, sales and marketing issues.
Vinge has advised LumenRadio AB (publ) (“LumenRadio”) in connection with its listing on Nasdaq First North Growth Market. The prospectus was published on 28 November 2022 and the first day of trading occurred on 8 December 2022.
Tidnings AB Marieberg, a subsidiary of Bonnier News Group AB, has announced a public cash offer of SEK 455 million to the shareholders of Readly International AB (publ).
Vinge advises Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with its sale of stake in its social infrastructure portfolio for public education to Brookfield for SEK 9.2 billion. The transaction also includes earn out payments up to SEK 1.2 billion.
The loan agreement with the European Investment Bank (EIB) grants Oncopeptides access to a renewed unsecured loan facility of up to EUR 30 million. The loan facility agreement is divided into three tranches, each with a maturity of five years, which will become available if the company, inter alia, satisfies certain milestones related to the ongoing commercialization of Pepaxti® in Europe and a potential relaunch of Pepaxto® in the US. In connection with the loan agreement, Oncopeptides has entered into a renewed warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.
Aneo Renewables Holding AS has made a public mandatory bid for all shares in Scandinavian Biogas Fuels International AB. The offer values the shares of Scandinavian Biogas at approximately SEK 670 million. Vinge advises Aneo.
Scandinavian Biogas Fuels International AB has carried out a directed share issue of SEK 326 million. Vinge advised Aneo Renewables Holding AS (Scandinavian Biogas’ largest shareholder).
Vinge has advised Re:NewCell, a textile-to-textile recycling company listed on Nasdaq First North Premier Growth Market, in connection with a directed share issue whereby the company raised proceeds of approximately SEK 158 million before issue costs.
